| Date | Event | Description |
|---|---|---|
| 6 February 2018 | Review declared as stable | Trastuzumab is now an established part of standard treatment and it is highly unlikely that new trials will be confined to trials of trastuzumab‐containing regimens compared to chemotherapy regimens alone. There is now an emphasis on combining different anti‐HER2 agents and therefore new Cochrane review topics will reflect this change in practice. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.